Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Increased mRNA levels of Xeroderma pigmentosum complementation group B (XPB) and Cockayne's syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum resistant human ovarian cancer tissues
Autore:
Dabholkar, M; Thornton, K; Vionnet, J; Bostick-Bruton, F; Yu, JJ; Reed, E;
Indirizzi:
NCI, Med Branch, Med Ovarian Canc Sect, NIH, Bethesda, MD 20892 USA NCI Bethesda MD USA 20892 Ovarian Canc Sect, NIH, Bethesda, MD 20892 USA
Titolo Testata:
BIOCHEMICAL PHARMACOLOGY
fascicolo: 11, volume: 60, anno: 2000,
pagine: 1611 - 1619
SICI:
0006-2952(200012)60:11<1611:IMLOXP>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
MISMATCH REPAIR DEFICIENCY; NUCLEOTIDE EXCISION-REPAIR; MESSENGER-RNA LEVELS; DNA-REPAIR; CELL-LINES; CISPLATIN SENSITIVITY; TRANSCRIPTION FACTOR; ACQUIRED-RESISTANCE; BTF2 TFIIH; GROUP-F;
Keywords:
XPB; CSB; ovarian cancer; platinum compounds; MDR1; MT-II;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
45
Recensione:
Indirizzi per estratti:
Indirizzo: Reed, E NCI, Med Branch, Med Ovarian Canc Sect, NIH, Bldg 10,Rm 12N226, Bethesda, MD 20892 USA NCI Bldg 10,Rm 12N226 Bethesda MD USA 20892 Bethesda, MD 20892 USA
Citazione:
M. Dabholkar et al., "Increased mRNA levels of Xeroderma pigmentosum complementation group B (XPB) and Cockayne's syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum resistant human ovarian cancer tissues", BIOCH PHARM, 60(11), 2000, pp. 1611-1619

Abstract

Tumor tissue specimens from human ovarian cancer patients were assessed for relative mRNA abundance levels of several genes thought to be involved inthe development of in vitro drug resistance in this disease. Higher mRNA levels of Xeroderma pigmentosum group B (XPB), which links DNA repair with DNA transcription, and of Cockayne's syndrome group B (CSB), which is essential for gene-specific repair, were observed in tumor tissues that were clinically resistant to platinum-based chemotherapy, as compared with tissues from patients responding to therapy. In a cohort of 27 patients, mRNA levelsof XPB averaged 5-fold higher in platinum-resistant tumors (P = 0.001); and for CSB, mRNA levels averaged 6-fold higher but with greater variability (P = 0.033). Concurrently, these platinum-resistant tumor tissues did not exhibit significantly higher mRNA levels for the MDR1 (multidrug-resistance)gene (P = 0.134) or of the metallothionein-II (MT-II) gene (P = 0.598). Since these platinum-resistant tumors also show higher mRNA levels of ERCC1 and XPA, platinum resistance appears to be associated with concurrent up-regulation of four genes (XPA, ERCC1, XPB, and CSB). These four genes participate in DNA damage excision activity, gene-specific repair, and linkage of DNA repair with DNA transcription. These data suggest that concurrent up-regulation of genes involved in nucleotide excision repair may be important inclinical resistance to platinum-based chemotherapy in this disease. (C) 2000 Elsevier Science Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/06/18 alle ore 00:48:20